part i item 1 . business . merck & co. , inc . ( 201cmerck 201d or the 201ccompany 201d ) is a global health care company that delivers innovative health solutions through its prescription medicines , vaccines , biologic therapies , animal health , and consumer care products , which it markets directly and through its joint ventures . the company 2019s operations are principally managed on a products basis and are comprised of four operating segments , which are the pharmaceutical , animal health , consumer care and alliances segments , and one reportable segment , which is the pharmaceutical segment . the pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the company or through joint ventures . human health pharmaceutical products consist of therapeutic and preventive agents , generally sold by prescription , for the treatment of human disorders . the company sells these human health pharmaceutical products primarily to drug wholesalers and retailers , hospitals , government agencies and managed health care providers such as health maintenance organizations , pharmacy benefit managers and other institutions . vaccine products consist of preventive pediatric , adolescent and adult vaccines , primarily administered at physician offices . the company sells these human health vaccines primarily to physicians , wholesalers , physician distributors and government entities . the company also has animal health operations that discover , develop , manufacture and market animal health products , including vaccines , which the company sells to veterinarians , distributors and animal producers . additionally , the company has consumer care operations that develop , manufacture and market over-the- counter , foot care and sun care products , which are sold through wholesale and retail drug , food chain and mass merchandiser outlets , as well as club stores and specialty channels . the company was incorporated in new jersey in for financial information and other information about the company 2019s segments , see item 7 . 201cmanagement 2019s discussion and analysis of financial condition and results of operations 201d and item 8 . 201cfinancial statements and supplementary data 201d below . all product or service marks appearing in type form different from that of the surrounding text are trademarks or service marks owned , licensed to , promoted or distributed by merck , its subsidiaries or affiliates , except as noted . all other trademarks or services marks are those of their respective owners . product sales sales of the company 2019s top pharmaceutical products , as well as total sales of animal health and consumer care products , were as follows: .

****************************************
( $ in millions ), 2013, 2012, 2011
total sales, $ 44033, $ 47267, $ 48047
pharmaceutical, 37437, 40601, 41289
januvia, 4004, 4086, 3324
zetia, 2658, 2567, 2428
remicade, 2271, 2076, 2667
gardasil, 1831, 1631, 1209
janumet, 1829, 1659, 1363
isentress, 1643, 1515, 1359
vytorin, 1643, 1747, 1882
nasonex, 1335, 1268, 1286
proquad/m-m-rii/varivax, 1306, 1273, 1202
singulair, 1196, 3853, 5479
animal health, 3362, 3399, 3253
consumer care, 1894, 1952, 1840
other revenues ( 1 ), 1340, 1315, 1665
****************************************

other revenues ( 1 ) 1340 1315 1665 ( 1 ) other revenues are primarily comprised of alliance revenue , miscellaneous corporate revenues and third-party manufacturing sales . on october 1 , 2013 , the company divested a substantial portion of its third-party manufacturing sales . table of contents .

Question: what is the growth rate in total sales in 2012?
Program: subtract(47267, 48047), divide(#0, 48047)
Answer: -0.01623